Seth Lerner, MD, defines what places a bladder cancer patient into the BCG unresponsive category and treatment options in these cases. He touches on valrubicin, summarizes data regarding off-trial options such as gemcitabine, docetaxel, and the gem/doce combination, and discusses clinical trials for CG0070, Ad-IFN, and atezolizumab.
Read More
Michael S. Cookson, MD, describes the components of a quality transurethral resection of bladder tumor (TURBT), enhanced detection technologies such as blue light cystoscopy and narrow band imaging (NBI), and the induction of these new technologies into the American Urological Association (AUA) and Society of Urologic Oncology (SUO) bladder cancer guidelines and common practice.
Read More
Peter Black, MD, FRCSC, discusses the benefits and limitations of the currently FDA approved urinary biomarkers for bladder cancer. He defines criteria for the ideal biomarker, which would reduce the need for other diagnostic tests, have a high sensitivity and specificity rate, and be cost-effective for patients, as well as the possibility of using biomarkers in place of cystoscopy.
Read More
Ashish M. Kamat, MD, articulates the discrepancies in the American Urological Association and European Association of Urology bladder cancer treatment guidelines, challenges in defining a risk-stratification scale for the disease, knowledge gaps regarding BCG failure, and other factors that hinder the urological community’s ability to design quality clinical trials for non-muscle invasive bladder cancer.
Read More
In this presentation, Dr. Patrick Walsh expands upon Dr. Veda N. Giri’s introduction to the Philadelphia Prostate Cancer Consensus 2017. While she set forth the goals of the meeting and emphasized the importance of drafting centralized guidelines for genetic testing, Dr. Walsh focuses on PSA testing. He summarizes the past of PSA testing to give context to the urological community’s goals for the future.
Read More